Seeking Alpha

Gilead's (GILD +1.9%) once-daily Sofosbuvir hepatitis C drug met the goals of a fourth Phase III...

Gilead's (GILD +1.9%) once-daily Sofosbuvir hepatitis C drug met the goals of a fourth Phase III study, this time in patients who had failed prior treatments. With all four trials providing positive results, Gilead is on track to file regulatory applications in the EU and U.S. in Q2. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|